Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: Associated factors and prediction of mortality

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Artunc, Ferruh ^a   Nowak, Albina ^b   Mueller, Christian ^c   Breidthardt, Tobias ^c   Twerenbold, Raphael ^c   Wagner, Robert ^a   Peter, Andreas ^a   Haering, Hans Ulrich ^a   Ebmeyer, Stefan ^d   Friedrich, Bjoern ^a,e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d Fisher Scientific GmbH   (Germany)

^e Dialysis Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; BETA 2 MICROGLOBULIN; COPEPTIN; ENDOTHELIN 1;

AGED; ARTICLE; BLOOD ANALYSIS; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DIURESIS; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SURVIVAL TIME; UPREGULATION;

ADRENOMEDULLIN; AGED; CAUSE OF DEATH; COMORBIDITY; ENDOTHELIN-1; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RENAL DIALYSIS;

EID: 84899879818     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086148     Document Type: Article

References (25)

1. Hinson JP, Kapas S, Smith DM (2000) Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 21: 138-167. (Pubitemid 32275593)
2. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2005) Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 51: 1823-1829. (Pubitemid 41368172)
3. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112-119. (Pubitemid 43032474)
4. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 52: 1144-1151. (Pubitemid 43794428)
5. Apple FS, Murakami MM, Pearce LA, Herzog CA (2002) Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106: 2941-2945. (Pubitemid 35424746)
6. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, et al. (2002) Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 40: 68-75. (Pubitemid 34701213)
7. Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A (2005) Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 112: 3088-3096. (Pubitemid 43113440)
8. Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, et al. (2009) Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care 13: R122.
9. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, et al. (2010): Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55: 2062-2076.
10. Artunc F, Mueller C, Breidthardt T, Twerenbold R, Peter A, et al. (2012) Sensitive troponins - which suits better for hemodialysis patients? Associated factors and prediction of mortality. PLoS One 7: e47610.
11. Artunc F, Mueller C, Breidthardt T, Twerenbold R, Rettig I, et al. (2012) Comparison of the diagnostic performance of three natriuretic peptides in hemodialysis patients: which is the appropriate biomarker? Kidney Blood Press Res 36: 172-181.
12. Potocki M, Breidthardt T, Mueller A, Reichlin T, Socrates T, et al. (2010) Copeptin and risk stratification in patients with acute dyspnea. Crit Care 14: R213.
13. Gouya G, Sturm G, Lamina C, Zitt E, Freistatter O, et al. (2011) The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort. PLoS One 6: e17803.
14. Fenske W, Wanner C, Allolio B, Drechsler C, Blouin K, et al. (2011) Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol 22: 782-790.
15. Spinar J, Ludka O, Dusek L, Vitovcova L, Sobotova D, et al. (2007) Neurohumoral activity, heart failure and prognosis in patients with end-stage renal disease treated by hemodialysis. Kidney Blood Press Res 30: 347-357. (Pubitemid 47482068)
16. Jankowska EA, Filippatos GS, von HS, Papassotiriou J, Morgenthaler NG, et al. (2011) Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. PLoS One 6: e14506.
17. Khan SQ, Dhillon O, Struck J, Quinn P, Morgenthaler NG, et al. (2007) Cterminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Am Heart J 154: 736-742. (Pubitemid 47429589)
18. Suzuki Y, Itoh H, Katagiri F, Sato F, Kawasaki K, et al. (2013) Relationship between plasma mid-regional pro-adrenomedullin level and resistance to antihypertensive therapy in stable kidney transplant recipients. Peptides 48: 45-48.
19. Yoshihara F, Ernst A, Morgenthaler NG, Horio T, Nakamura S, et al. (2007) Midregional proadrenomedullin reflects cardiac dysfunction in haemodialysis patients with cardiovascular disease. Nephrol Dial Transplant 22: 2263-2268. (Pubitemid 47244704)
20. Yoshihara F, Horio T, Nakamura S, Yoshii M, Ogata C, et al. (2005) Adrenomedullin reflects cardiac dysfunction, excessive blood volume, and inflammation in hemodialysis patients. Kidney Int 68: 1355-1363. (Pubitemid 43246457)
21. Federico C (2010) Natriuretic Peptide system and cardiovascular disease. Heart Views 11: 10-15.
22. Ishimitsu T, Ono H, Minami J, Matsuoka H (2006) Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 111: 909-927. (Pubitemid 44118439)
23. Oyar EO, Kiris I, Gulmen S, Ceyhan BM, Cure MC, et al (2012) The protective effect of adrenomedullin on renal injury, in a model of abdominal aorta cross-clamping. Thorac Cardiovasc Surg 60: 5-10.
24. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM (2002) Long-term adrenomedullin administration in experimental heart failure. Hypertension 40: 667-672. (Pubitemid 35278603)
25. Davenport A (2011) Role of dialysis technology in the removal of uremic toxins. Hemodial Int 15 Suppl 1: S49-S53.